Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DSP 0390

Next Previous
X
Search
Drug Profile

DSP 0390

Alternative Names: DSP-0390; TP-0390

Latest Information Update: 28 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sumitomo Dainippon Pharma; Tolero Pharmaceuticals
  • Developer Sumitomo Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EBP protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Glioma; Solid tumours

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Glioma(Recurrent) in Japan (PO)
  • 10 Oct 2024 Washington University School of Medicine in collaboration with Sumitomo Pharmaceuticals America plans an early phase I trial for Glioma (Recurrent) in USA (PO) (NCT06636162)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours in Japan (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top